Valsartan vs Losartan for Initial Hypertension Treatment

Efficacy Comparison

The European Society of Cardiology recommends losartan as a superior option to atenolol in reducing cardiovascular events, particularly stroke, in hypertensive patients with left ventricular hypertrophy 1, 2
The addition of valsartan to treatment regimens in high-risk hypertensive patients resulted in a marked reduction (40%) in stroke incidence compared to other non-ARB treatments, as demonstrated by the JIKEI HEART study 3

The American Heart Association suggests that losartan 50mg daily may have a trend toward increased mortality compared to captopril in post-MI patients, possibly due to inadequate dosing 4
Valsartan was as effective as captopril for reducing cardiovascular events in high-risk post-MI patients, as demonstrated by the VALIANT trial 4, 5
The European Society of Cardiology indicates that valsartan can be used in elderly patients without dose adjustment 1
Higher doses of losartan (150mg daily) were superior to lower doses (50mg daily) for optimal efficacy, as shown by the HEAAL trial 5

Inadequate dosing of ARBs, such as losartan, may lead to suboptimal outcomes, as seen in the OPTIMAAL trial 4
Neither ARB should be combined with ACE inhibitors or direct renin inhibitors due to increased risk of adverse events without additional benefit 5
Monitoring renal function and potassium levels is essential when initiating therapy, especially in patients with renal impairment, as recommended by the American College of Cardiology 4